The one-year results of half-dose photodynamic therapy with verteporfin in chronic or recurrent central serous chorioretinopathy.
OBJECTIVE
To evaluate the one-year results of half-dose photodynamic therapy with verteporfin in chronic or recurrent central serous chorioretinopathy (CSC).


METHODS
A Retrospective, consecutive case series. Twenty-seven eyes of 27 patients with chronic symptomatic CSC or recurrent CSC underwent photodynamic therapy (PDT) with half-dose (3 mg/m2) verteporfin. The demographic data such as age, side, gender spot sizes of laser photodynamic therapy (PDT) were recorded. The primary outcomes were the best correct visual acuity (BCVA), central foveal thickness using the optical coherence tomography (OCT) and complication were recorded as secondary outcome at baseline, month 1,3,6 and 12 post PDT RESULTS: At 12 months after half-dose PDT the mean logMAR BCVA improved from 0.32 to 0.18 (p = 0.001), the mean central foveal thickness decreased from 375.52 microm to 186.52 mirom (p < 0.001). The results also showed significant improvement of logMAR BCVA and decreased central foveal thickness after 1 month (0.32 to 0.22, p = 0.003 and 375.52 microm to 175.41 microm, p < 0.001) and maintained the results until one-year follow-up. Twenty-five eyes (92.59%) showed complete resolution of subretinal fluid at 1 month, 27 patients (100%) showed complete resolution at 3 month and all sustained the complete resolution until the last visit. No serious complications were recorded during and after the treatment.


CONCLUSIONS
The half-dose PDT in area of fluorescein leakage is one of the effective treatment options for chronic or recurrent CSC, especially in patients who cannot be performed by focal laser photocoagulation. The treatment sustained the good visual results and has no serious complications up to one-year.
Department of Ophthalmology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand. jpichai@hotmail.com
Pichai
P
Jirarattanasopa
Mansing
M
Ratanasukon
Patama
P
Bhurayanontachai
D000328:Adult; D056833:Central Serous Chorioretinopathy / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000008:administration & dosage*; D011166:Porphyrins / Q000008:administration & dosage*; D012189:Retrospective Studies; D016896:Treatment Outcome; D000077362:Verteporfin
D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin